Published: 2017-10-25

A comparative study of efficacy of febuxostat and allopurinol regimens in patients of hyperuricemia

Supratik Das, Vijay Kumar, Harjinder Singh, Jasbir Singh, . Hemraj, Arshiya Sehgal


Background: Gout, resulting from the precipitation of urate crystals in the tissues and the subsequent inflammatory response, causes an exquisitely painful distal monoarthritis alongwith joint destruction, subcutaneous deposits (tophi), renal calculi. The main culprit is uric Acid, which is a waste product formed due to purine metabolism. Gout Patients either produce excess Uric acid or are unable to excrete Uric acid produced in normal conditions. Uric acid lowering therapy (ULT) has become popular regarding management of gout. Nowadays. 2 drugs which are responsible for decreasing synthesis of Uric acid are Febuxostat and Allopurinol. The purpose of this study is to determine efficacy of Febuxostat and Allopurinol experienced by patients during course of therapy.

Methods: It was an open, prospective, observational, non-invasive, parallel and randomised study, conducted at the Outpatient Department of Urology, Rajindra Hospital, Patiala. It had 60 patients of gout, out which, 30 patients were administered Febuxostat and 30 patients were administered Allopurinol. For each patient, history regarding drug intake was taken, along with analysis of Serum Uric acid profile before prescription and during follow up.

Results: The mean age selected for study was 47 years for Febuxostat group and 43 years for Allopurinol group. Mean Urate (mg%) in pre-treatment stage of patients of Febuxostat group is about 8.28 whereas for Allopurinol group its about 8.61. Mean urate levels after 4 follow ups (10 days each) were conducted. The mean Urate level at 10, 20, 30, 40 days were conducted at each group which were found to be statistically significant and the results of Febuxostat group was found to be favourable.

Conclusions: Febuxostat, (40mg) given at daily dose was found to have higher efficacy than allopurinol, at a dose of 100mg (zyloric) which is the most commonly prescribed dose in order to lower the serum urate level.


Allopurinol, Alloxanthine, Febuxostat, Gout, Uric acid, Xanthine oxidase

Full Text:



Gilman A, Goodman L. Goodman’s and Gilman’s: The Pharmacological basis of Therapeutics: Anti-inflammatory, Antipyretic, and Analgesic Agents; Pharmacotherapy of Gout: Introduction. 12th Ed. The McGraw-Hill Companies, Inc; 2011.

Al-Allaf AW. Gout: evidence based update with new therapeutic strategies. Sudan Med J. 2012 Dec;48(3):165-75.

Kelly VM, Krishnan E. Febuxostat for the treatment of hyperuricemia in patients with gout. Int. J. Clin. Rheumatol. 2011;6(5):485-93.

Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-7.

Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6.

Wyngaarden JB, Kelley WN. Gout and Hyperuricemia. New York: Grune & Stratton; 1976.

Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93:817-21.

Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761-76.

Sharma HL, Sharma KK. Principles of Pharmacology: NSAIDs, Drugs for Gout and Antirheumatoid drugs. 2nd ed. Hyderabad: Paras Medical Publisher; 2013.

Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology: Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Nonopioid analgesics and Drugs used in Gout. 12th Ed. New Delhi: Mc Graw Hill Education; 2012.

Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA. 1989;86:9412-6.

Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care Res. 2012; Oct;64(10):1447-61.

Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281-6.

Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the golden standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15(1):22-4.

Janssen HJ, Fransen J, van de Lisdonk EH, van Riel PL, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120-6.

Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. Arthritis Rheum. 1965;8:1123-33.

Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15:189-92.

Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42:12-5.

Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis. 1986;45:858-64.

Fam AG, Stein J, Rubenstein J. Gouty arthritis in nodal osteoarthritis. J Rheumatol. 1996;23:684-9.

Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6.

Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501-5.

De Miguel E, Puig JG, Castillo C, Peiteado D, Torres RJ, Martín-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Annals of the rheumatic diseases. 2011 Sep.

Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henríquez P, Hernández-Díaz C, Vargas A, et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Research & Therapy. 2011 Jan 17;13(1):R4.

Tausche AK, Jansen TL, Schroder HE, Bornstein SR, Aringer M, Ladner UM. Gout-Current Diagnosis and Treatment. Dtsch Arztebl Int. 2009;106 (34-35):549-55.

Bisht M, Bist SS. Febuxostat. A Novel Agent for Management of Hyperuricemia in Gout. Indian J Pharm Sci. 2011 Nov-Dec;73(6):597-600.

Reinders HK, Jansen TLTA. Management of hyperuricemia in gout: focus on febuxostat. Clinical Interventions in Aging. 2010;5:6-18.

Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-6.

Gout HR. Looking beyond Allopurinol. Medicine Update. 2010;20:822-5.

Cada DJ, Levien TL, Bake DE. Febuxostat. Hosp Pharm. 2009;44:688- 99.

Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Pharmacol. 2008;65:355-63.

Song GG, Lee YH. Comparative Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Hyperuricemia: A Bayesian Network Meta-analysis. J Rheum Dis. 2015;22(6):356-65.

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology: Anti inflammatory and immunosuppressant drugs. 7th Ed. Livingstone: Churchill Elsevier; 2012.

Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Pala WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61.

Wallace SL, Robinson H, Masi AT, Decker JL, Mccarty DJ. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis & Rheumatology. 1977 Apr 1;20(3):895-900.

Sarkin AJ, Gnanasakthy A, Lale RS, Choi KJ, Hirsch JD. A Composite Endpoint Measure to Consolidate Multidimensional Impact of Treatment on Gouty Arthritis. Open Journal of Rheumatology and Autoimmune Diseases. 2013;3:159-64.

Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology. 2009;48:ii15-9.